Research findings announced at the San Antonio Breast Cancer Symposium in Texas this week show that a class of drugs called Anastrozole can cut the rate of recurrence of breast cancer by 76 per cent, with fewer side effects than the drug that is currently used, Tamoxifen.
Martha asks Delyth Morgan, Chief Executive of Breakthrough Breast Cancer,what the new drugs do, who will benefit and when they will be available to women in the UK?
